Work

Drug targets to improve the outcome of hormonal adjuvant therapy in breast and prostate cancers

Year: 2013
Type: article
Abstract: Tamoxifen and aromatase inhibitors (AI) are a mainstay in the treatment of estrogen receptor (ER)-positive breast cancer.However, long-term treatment of women at high risk for breast cancer leads to development of resistance against the drug and reduces the incidence of both invasive and non-invasive ER-positive breast cancer in only approximately 50% of cases.For resistance to develop during either hormone depletion (AI) treatment or tamoxifen adjuvant therapy, there must be a fraction of cells that must maintain a basal level of cell cycling.Growth and proliferation of these latent tumor cells later lead to the development of resistance.Our lab has shown that: "Under conditions of hormonal adjuvant treatment the estrogen receptor apoprotein supports breast cancer cell cycling through the retinoic acid receptor (RAR) -α1 apoprotein".RARα1 is the only isoform expressed in breast tumor cells and it being genetically redundant, targeting it specifically may lead to improved outcome of current hormonal adjuvant therapies with minimal side effects.We have synthesized a high affinity RARα-specific antagonist, AGN194301, as a carrier molecule to selectively target RARα.AGN194301 by itself did First and fore most I would like to express my sincere gratitude to my major advisor Dr.
Language: English
Subfield: Endocrinology
Open Access status: green
OpenAlex ID: W2469904948
FWCI:
Cites: 477
Cited by: 1
Related to: 10